DCVMN 2020

Pandemic Response: the critical role of DCVMs

Anita Zaidi
4 PILLARS GUIDE THE DEPLOYMENT OF FOUNDATION RESOURCES TO SUPPORT THE GLOBAL RESPONSE

**COVID-19 Mission:** Accelerate global efforts to curb the impact of the coronavirus pandemic by deploying foundation resources in support of four key pillars

1. **Accelerate detection and suppression**
   - Accelerate, fill gaps in, and inform global response\(^1\) through partners with existing capacity for rapid action

2. **Protect the most vulnerable**
   - Rapidly strengthen capacity and coordination\(^2\) to detect and respond to COVID-19 in target LMICs

3. **Develop products for a sustained response**
   - Leverage foundation’s unique capacity to coordinate and fill gaps in COVID-19 product development\(^3\) while securing global access

4. **Minimize societal and economic impact**
   - Promote responses that balance health outcomes and economic recovery minimizing the negative impact on societies and individuals

---

\(^1\) Includes detection, testing, contact tracing, case isolation, etc. Also includes designing and implementing social distancing, personal & environmental hygiene, messaging/comms, etc.

\(^2\) Includes disease surveillance, modeling & analytics, development of costed response plans, resource mobilization and alignment, etc.

\(^3\) Includes R&D, product introduction (Dx, Rx, Vx), testing/scaling service delivery innovations, improving commodities availability/access, etc.
THE FOUNDATION HAS COMMITTED MORE THAN $350M TO SUPPORT THE GLOBAL RESPONSE TO COVID-19

Foundation’s total new commitments along our 4 pillars:

$350M+

In addition to our $350M+ in commitments, the foundation is…

Leveraging our $2.5 billion Strategic Investment Fund to address market failures and incentivize private enterprise to develop affordable and accessible health products

Providing technical assistance, when requested, to a variety of multilateral organizations and government agencies to help accelerate the response

In addition to new funds committed to COVID-19 response, the foundation continuing to address our program goals, maintaining commitments to efforts in these areas, like malaria, TB, and global education
CATALYZING VACCINE DEVELOPMENT VIA THE COVAX PILLAR

The COVAX pillar is a collaboration between the following organizations:

- **CEPI**: Development and manufacturing
- **Gavi**: Procurement and delivery targeting 2 billion doses by the end of 2021
- **World Health Organization**: Policy, safety, regulation and allocation
WHAT WE ARE LEARNING THROUGH COVID-19

Nationalist procurement risk inhibiting LMIC access to lifesaving vaccines

Wealthy countries have funded R&D and secured access for domestic populations through bilateral deals…

... and without DCVMs, supply for LMICs would depend almost entirely on HIC willingness to provide leftover doses

Source: Financial Times September 23, 2020
Source: BMGF - A three-part plan to eliminate COVID-19
Source: BMGF - A three-part plan to eliminate COVID-19
EQUITABLE DISTRIBUTION REDUCES OVERALL DEaths

Applying influenza modeling methods to real life events highlights the risk of an HIC focused response

MODELED PERCENTAGE OF DEATHS (COMpared TO NO VACCINE)

- 33% deaths averted when vaccine is distributed to high-income countries first
- 61% deaths averted when vaccine is distributed to all countries proportional to population

An equitable distribution of the first 2B (out of 3B) doses of an 80% effective COVID-19 vaccine could lead to nearly twice as many deaths being averted as opposed to an exclusive distribution to HIC.

Source: Bill & Melinda Gates Foundation, 2020 Goalkeepers Report. Data from MOBS LAB, Northeastern University
DCVM EXPERTISE AND CAPACITIES PLAY A PIVOTAL ROLE IN ENABLING COVID-19 ACCESS

For example, global distribution of available excess fill/finish capacity highlights the potential for DCVM partnerships to ensure global supply and access beyond the US and Europe.

BMGF is working with DCVMs to advance COVID-related goals as part of global effort to discover and manufacture vaccines.

Note: Where companies do not provide data 10% availability assumed.
Source: Drug Product CEPI BMGF PATH CHAI Database (21 May 2020)
### HOW DCVM’S ENABLE EQUITABLE ACCESS TO VACCINES

#### Key advantages of DCVM’s:

<table>
<thead>
<tr>
<th>Category</th>
<th>Advantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality/Reliability</td>
<td>• Proven track record of successful tech transfers and innovative approaches</td>
</tr>
<tr>
<td>Cost/Affordability</td>
<td>• Ability to produce vaccines at a rate that meets the needs of suppliers and country specific requirements</td>
</tr>
<tr>
<td>Reach</td>
<td>• DCVM’s reach Gavi countries and fill gaps in vaccine availability</td>
</tr>
<tr>
<td>Commitment</td>
<td>• A shared purpose ensures equitable access</td>
</tr>
</tbody>
</table>
DCVM’S ARE CRITICAL FOR GLOBAL HEALTH AND PANDEMIC RESPONSE

- Strengthened network and innovation
- R&D to meet developing world needs
- Continued engagement
- Equitable access to safe, affordable and reliable Vx.
- International recognition of DCVM’s value